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Abstract
Native Chlamydia trachomatis mouse pneumonitis major outer membrane protein (nMOMP)
induces effective protection against genital infection in a mouse challenge model. The conformation
of nMOMP is crucial to confer this protective immunity. To achieve a better understanding of the
conformational behavior and stability of nMOMP, a number of spectroscopic techniques are
employed to characterize the secondary structure (circular dichroism), tertiary structure (intrinsic
fluorescence) and aggregation properties (static light scattering and optical density) as a function of
pH (3-8) and temperature (10-87.5°C). The data are summarized in an empirical phase diagram (EPD)
which demonstrates that the thermal stability of nMOMP is strongly pH-dependent. Three distinctive
regions are seen in the EPD. Below the major thermal transition regions, nMOMP remains in its
native conformation over the pH range of 3-8. Above the thermal transitions, nMOMP appears in
two different structurally altered states; one at pH 3-5 and the other at pH 6-8. The EPD shows that
the highest thermal transition point (~ 65°C) of nMOMP is near pH 6. Several potential excipients
such as arginine, sodium citrate, Brij 35, sucrose and guanidine are also selected to evaluate their
effects on the stability of nMOMP. These particular compounds increase the aggregation onset
temperature of nMOMP by more than 10°C, without affecting its secondary and tertiary structure.
These results should help formulate a vaccine using a recombinant MOMP.
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Introduction
Chlamydia trachomatis is the most prevalent sexually transmitted bacterial pathogen.1-3 It is
estimated that 100 million new infections occur every year with a high proportion of them
affecting young, sexually active individuals. In the United States, 3-4 million new cases of C.
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trachomatis infection occur annually. In females, cervicitis and urethritis are the most common
acute manifestations. Their long-term sequelae include pelvic inflammatory disease, chronic
abdominal pain, ectopic pregnancy and infertility 4. In males, urethritis is the most frequent
clinical presentation.4 In newborns under six months of age, C. trachomatis is the most common
cause of pneumonia and conjunctivitis. In addition, in countries with limited sanitary resources,
trachoma which is an infectious eye disease and the leading cause of preventable blindness,
and lymphogranuloma venereum (LGV) which may lead to severe systemic complications, are
frequent clinical presentations of C. trachomatis infections.5
Efforts to vaccinate individuals against trachoma were initiated several decades ago.6 Humans
and monkeys were immunized with live or inactivated whole organisms. Although no
vaccination programs were implemented, several practical lessons were learned from these
trials. Specifically, protection was found to be, for the most part, serovar specific and short
lived. In poorly protected individuals, re-exposure to C. trachomatis resulted in more severe
disease than that observed in nonvaccinated controls. As a consequence of this possible risk
of vaccine-related immunopathology, it was proposed that the development of a subunit
vaccine would be a preferred alternative to avoid the potential harmful effects of preparations
containing the whole organism. In the last five decades, as the role of C. trachomatis in sexually
transmitted infections was elucidated, the main focus of vaccine development indeed has
shifted to the identification of target candidates that would induce protection against genital
infections.
Among the various vaccine candidates evaluated to protect against chlamydial infection, the
major outer membrane protein (MOMP) has been the antigen more thoroughly tested. DNA
sequencing of the MOMP from several C. trachomatis serovars showed that this protein has
four variable and five constant structural domains.7 Phylogenetic analysis of the nucleotide
sequence of MOMP supported the immunological classification of C. trachomatis isolates into
various serovars.8 This immunological classification was based on the cross-reactivity among
serum samples generated by inoculating mice with the various serovars. Two major complexes
delineated C (including serovars C, J, H, I, A, K and L3) and B (encompassing serovars B, Ba,
E, D, L1 and L2) as well as a B-related complex (G and F) were recognized.9 This classification
was further supported by protection studies using a mouse model.9 Animals immunized with
one serovar were subsequently protected against a challenge with the same, or a serologically
closely related isolate in the same complex, but not against a distantly related serovar.
Recently, a vaccine was formulated that was effective at controlling a genital infection and
preventing infertility in a mouse model.10 This vaccine was prepared by isolating the native
C. trachomatis mouse pneumonitis (MoPn; also referred as Chlamydia muridarum) MOMP
directly from the organism. Native MoPn MOMP (nMOMP) forms trimers that have a
predominant β–sheet structure and functions as a porin.11
Formulation development of membrane-associated proteins is a major challenge. The
conformation of MOMP plays a key role in the ability of this molecule to confer protective
immunity10, 12-14. In the current study, we provide a detailed biophysical characterization of
nMOMP in solution to better understand its thermal stability, which is assessed using a number
of spectroscopic techniques. The spectroscopic data are summarized in the form of an empirical
phase diagram (EPD), a matrix-based method which provides a comprehensive view of protein
stability.15, 16 The effect of several compounds on nMOMP thermal stability was also
investigated. Such molecules provide a starting point for further formulation development.
Furthermore, excipients that stabilize MoPn nMOMP can be candidates for the stabilization
of MOMP of other serovars, including humans.
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Preparation of native MoPn MOMP
The nMOMP (strain Nigg II; American Type Culture Collection (ATCC), Manassas, VA) was
grown in McCoy cells17. The extraction and purification of MOMP were performed as
previously described10. In brief, nMOMP was washed with PBS (pH 7.4) and treated with 25
μg/mL of DNAse for 2 h at 4°C. The preparation was centrifuged and the pellet was extracted
twice with 2% of (3-[(3-Cholamidopropyl)-dimethylammonio]-l-propane sulfonate)
(CHAPS); Anatrace, Maumee, OH), in 0.2 M phosphate buffer (pH 5.5) containing 1 mM
phenylmethylsulfonyl fluoride (PMSF; Calbiochem, San Diego, CA), 1 mM EDTA and 100
mM dithiotreitol (DTT; Roche Diagnostic Corporation, Indianapolis, IN). The pellet was then
extracted with 2% Anzergent 3-14 (n-Tetradecyl-N,N-dimethyl-3-ammonio-1-
propanesulfonate) (Z3-14); Anatrace) in the same buffer at 37°C. To further purify the nMOMP
the supernatant was applied to a 30 × 2 cm hydroxyapatite column (Bio-Gel HTP Gel; Bio-
Rad Laboratories; Hercules, CA) equilibrated with 0.02 M phosphate buffer (pH 5.5)
containing 0.1% Z3-14 and 1 mM each of EDTA, PMSF and DTT 17. The nMOMP was eluted
with a linear gradient from 0.02 to 0.5 M in the same buffer. The peak fractions were analyzed
by SDS-polyacrylamide gel electrophoresis (PAGE) and identified by Western blot using the
monoclonal antibody MoPn40 to nMOMP11. Mass spectrometry analysis18 and N-terminal
sequencing10 of nMOMP both revealed the material used in this study manifested a purity of
> 99%. In addition, extraction of nMOMP requires the use of DTT. However, the disulfide
bonds are not necessary to maintain trimer's structure.11 In this paper a homogenous form
(trimer form) of nMOMP was characterized.
Purified nMOMP was dialyzed overnight at 4°C against a series of 20 mM citrate-phosphate
buffers (I = 0.1) containing 0.05% (w/v) Zwittergent 3-14 at pH 3-8 at one unit increments.
Dialysis was performed using 10 kDa molecular mass cutoff Slide-A-lyzer dialysis cassettes
(Pierce, IL). The nMOMP was then concentrated via centrifugation at 1750×g at 4 °C using
10 kDa NMWCO Amicon ultrafiltration concentrators (Millipore, Billerica, MA). Protein
concentration was determined by measuring UV absorption at 280 nm using ε = 1.5 (mL-
mg−1-cm−1).
Far-UV circular dichroism (CD) spectroscopy
Samples of nMOMP (pH 3-8) were concentrated to 0.2 mg/mL and transferred to a sealed
quartz cuvette of 0.1 cm path length. The CD signal was measured at a 20 nm/min scanning
speed over the far-UV range of 260-190 nm using a Jasco J-810 spectropolarimeter (Great
Dunmow, UK) equipped with a 6-position Peltier temperature controller. CD spectra were
collected at 2.5 °C intervals from 10 to 87.5 °C and a 15 °C/hr heating rate. The CD signal at
216 nm was extracted from the spectra and followed as a function of temperature. The results
were plotted using Sigma Plot 8.0.
Intrinsic (Trp) fluorescence spectroscopy
The tryptophan fluorescence of nMOMP (0.1 mg/mL) was measured using a Photon
Technology International (PTI) 814 spectrofluorometer (Lawrenceville, NJ) equipped with a
4-position turret that is Peltier-controlled. An excitation wavelength of 295 nm (>95 % Trp
emission) was employed with a 2 nm slit width while the emission signal was collected from
300 to 400 nm with a slit width of 2 nm. The fluorescence spectra were measured at 2.5 °C
intervals over the temperature range of 10 to 87.5 °C with a step size of 1 nm and 1 second
integration time. The wavelength position of maximum emission was determined using a
polynomial derivative fitting method executed in Origin 7.0 software. The transition midpoint,
however, was difficult to determine at same pH values.
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The static light scattering intensity was measured simultaneously using a 1 nm slit width during
the fluorescence experiments employing a second photomultiplier located 180° to the
fluorescence detector. The scattering intensity at the excitation wavelength (295 nm) was
followed as a function of temperature and plotted using Sigma Plot 8.0 software.
Turbidity measurements
The optical density at 350 nm (OD350) was measured as a direct indication of solution turbidity
in nMOMP samples (0.05 mg/mL) in a 1 cm path length quartz cuvette. OD350 was recorded
using an Agilent 8453 diode-array spectrophotometer (Palo Alto, CA) while the temperature
was increased from 10 to 87.5 °C at 2.5 °C increments and with a 5 min equilibration time.
The results were plotted using Sigma Plot 8.0.
Empirical phase diagram (EPD)
The EPD method was employed to summarize the data obtained from the biophysical
measurements mentioned above. CD signal at 216 nm, intrinsic fluorescence maximum peak
position, static light scattering intensity and OD350 were normalized within each data set and
the resulting data were used to generate an EPD. Each block of color in the EPD represents the
overall contribution from three elementary colors (red, green and blue) that correspond to the
three largest eigenvalues at each temperature and pH, calculated from the normalized results.
19 A detailed description of this method is presented elsewhere.15, 16, 19-24 Changes in EPD
color usually indicate conditions under which conformational transitions take place as detected
by the experimental methods.
Excipient studies
Several excipients were included in this study at the following concentrations: 0.3 M arginine;
0.1% (w/v) Brij 35; 0.3 M guanidine-HCl; 0.2 M sodium citrate and 20% (w/v) sucrose. The
effects of excipients were assessed by monitoring OD350 of protein-excipient (0.05 mg/mL
protein concentration) mixtures for 2 h at pH 5 and 60 °C. Conditions for this assay were
identified from color changes in the EPD (see results). In addition, intrinsic fluorescence as
well as static light scattering measurements (as described above) of nMOMP (0.05 mg/mL)
were employed in the presence of excipients over the temperature range of 10-87.5 °C to study
stabilizer effect with the temperature midpoint of the major transition in Trp fluorescence was
determined using the sigmoidal fitting tool in Origin 7.0 software. CD melting experiments of
nMOMP (0.2 mg/mL) were performed only in presence of brij 35 and sucrose due to signal
interference by the other excipients.
Results
Biophysical characterization of nMOMP
In this study, far-UV CD and intrinsic fluorescence spectroscopy were employed to assess the
thermal stability of the secondary and tertiary structures of nMOMP, respectively. CD spectra
of nMOMP before and after the thermal melt are shown in Figure 1 for all pH values examined.
The CD signal at 10 °C suggests that nMOMP contains primarily β secondary structure. The
protein displays very little pH dependence in secondary structure composition at low
temperature. When the temperature reaches 87.5 °C, a significant loss of CD signal is observed
at pH 3-5. This might be due to the loss of secondary structure and/or the protein precipitation
at higher temperatures. The nMOMP at pH 6-8, in drastic contrast, manifests increased negative
ellipticities after the thermal melt. This could be due to an increased amount of aggregation in
solution which gives rise to the formation of intermolecular β sheets. The CD signal at 216 nm
was monitored as a function of temperature and the result is shown in Figure 2. A transition is
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observed at pH 3 near 45 °C while a similar transition is present at pH 4 and 5 at a much higher
temperature, 65 °C. The protein at pH 6 exhibits a downward transition (increase in negative
ellipticity) in the CD signal near 60 °C, and as the pH increases to 7 and 8, a similar transition
is located near 50 °C.
The intrinsic fluorescence of nMOMP was also measured under different pH and temperature
conditions. The peak position of the tryptophan fluorescence emission was extracted using a
polynomial-based method and the results are shown in Figure 3 as a function of temperature.
On the basis of peak position sensitivity to the polarity of their environment, the tryptophan
residues appear to be relatively buried at low temperatures, manifesting a peak position between
326 and 330 nm. The peak wavelength increases slightly as pH increases, suggesting more
solvent exposure at higher pH values. The peak position of all samples slowly increases as the
temperature increases followed by a transition above 30 °C. In addition, samples at pH 3-5
show large error bars at high temperature. This presumably results from sample precipitation
at higher temperatures which causes the sample to become more heterogeneous (see below).
Note that the fluorescence changes occur at significantly lower temperature than those seen in
the CD studies.
Static light scattering (Figure 4) measured during the intrinsic fluorescence experiments
displays a strong pH dependent behavior. The nMOMP at pH 3 undergoes an abrupt increase
in scattering intensity around 40 °C, followed by pH 4 at 45 °C, pH 5 near 55 °C and pH 6 near
60 °C. Samples at pH 7 and 8 exhibit only limited intensity changes in scattering compared to
lower pH conditions. The order of transition onset temperature is further verified by OD350
measurements (shown in Figure 5). The increase in OD350 correlates well with the transitions
revealed by static light scattering with one exception. At pH 6, no significant changes in
OD350 are seen as the temperature increases. This exception is probably due to higher
sensitivity of right-angle static light scattering than that of optical density measurements. The
results obtained with light scattering and optical density measurements suggest the presence
of particles with increasing sizes under thermal stress probably due to protein aggregation. This
behavior appears to be strongly dependent on pH. Furthermore, at pH 3-5, nMOMP also
precipitates, which is indicated by the sharp intensity decrease observed in both static light
scattering and OD350 of high temperatures. On the other hand, nMOMP at pH 6-8 may form
soluble aggregates as suggested by the more limited intensity increase.
The empirical phase diagram (EPD) approach has been demonstrated to be an efficient method
with which to summarize large volumes of biophysical data and that can be used to describe
conformational changes and association phenomena.16, 20, 21 Thus, an EPD was constructed
for nMOMP using data from the CD signal at 216 nm, the intrinsic fluorescence peak position,
the static light scattering intensity and the OD350 changes. A color presentation of the resultant
EPD is shown in Figure 6 over a pH-temperature plane. The brown-green area at low
temperatures (below 40 °C) presumably corresponds to the conditions under which nMOMP
exists in the native conformation. The upper left region of blue color indicates the protein
structure is greatly altered at lower pH (3-5) and high temperatures. At pH 6-8, a transition
“phase” exists between 40 and 60 °C where the color is slightly different from the area below.
This suggests a partially unfolded structure of nMOMP. As the temperature increases at pH
6-8, nMOMP transforms into a structurally altered state (dark-red region on the upper right).
A major application of EPDs is to reveal “stress” physical conditions (i.e. pH and temperature)
that can cause significant structural changes in a protein and therefore may be used in the
development of screening conditions for excipients.22, 23 After optimization, excipients
identified using accelerated experimental approaches often sustain the protective effect in long-
term storage scenarios.
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In a separate investigation, several excipients were identified to stabilize the native MOMP
from C. trachomatis serovar A under elevated temperatures (Middaugh et. al, unpublished
result). Five representative compounds identified from these analyses were included in the
current study and their effects on nMOMP structure stability were evaluated. Compounds
chosen for further study were 0.3 M arginine, 0.1% (w/v) Brij 35, 0.3 M guanidine-HCl, 0.2
M sodium citrate and 20% (w/v) sucrose in a pH 5 citrate-phosphate buffer. Spectroscopic
measurements as well as the more general EPD analysis reveal that nMOMP undergoes a
“marked apparent phase transition” between 40 and 60 °C at pH 3-5. Since extreme low pH
conditions are usually not preferred in pharmaceutical protein formulations, excipient studies
of nMOMP were performed at pH 5. Therefore, nMOMP at pH 5 was incubated with selected
excipients at 60 °C and the turbidity at OD350 was monitored for two hours (shown in Figure
7A). An OD increase of protein alone is triggered after 20 minutes of incubation and continues
to progress. In contrast, the addition of the selected excipients to nMOMP, stabilizes the OD
at baseline level. Intrinsic fluorescence and static light scattering were also measured in the
presence of the five compounds and the same heating rate was applied from 10 to 87.5 °C. A
delay (of about 10 °C) is observed in the light scattering transition (Figure 7B) while the
excipients show no significant effect on the intrinsic fluorescence emission transition midpoint
(Table 1). Furthermore, two excipients (Brij 35 and sucrose) were incubated with nMOMP in
a CD experiment at pH 5 and the results indicate no change in the thermal stability of the
secondary structure (data not shown). Arginine, guanidine and sodium citrate interfere strongly
with the CD absorption and were, therefore, excluded from this analysis.
Discussion
Biophysical methods have been widely employed to better understand the structural properties
and to assess the stability of protein pharmaceuticals.15, 24 In this study, we employed a
combination of methods including CD, intrinsic fluorescence, static light scattering and
turbidity measurements to gain critical information concerning the stability of nMOMP, an
important vaccine candidate. Together with these spectroscopic measurements, a wide range
of pH and temperature conditions were applied to induce nMOMP structure changes. Earlier
studies have shown the native conformation of an MOMP to be a trimer containing
predominately β-sheet structure with demonstrated function as a porin.11 Other porins such as
matrix porin (OmpF) and OmpL1 from gram-negative bacteria have also been shown to have
high β-strand contents. 25, 26 CD experiments confirm that nMOMP is composed of
predominately β sheet and that the secondary structure does not vary significantly over the pH
range of 3 to 8 at low temperature. Marked differences in CD-detected nMOMP secondary
structure stability, however, exist among the various pH conditions. The protein at pH 3 seems
to be the least stable with an early CD signal loss near 45 °C while a similar event initiates
above 60 °C at pH 4 and 5. As the pH increases to 6 or higher, a gain in negative ellipticity is
observed at 50 °C. An increase in negative CD ellipticity between 215 and 220 nm is generally
an indicative of increased inter-molecular β structure.27, 28 The tertiary structure as detected
by intrinsic fluorescence changes of nMOMP starts to change significantly between 30 and 40
°C. Again the onset temperatures are pH-specific. Clearly, nMOMP manifests lower thermal
transition points of its tertiary than its secondary structure over the pH range of 3-8, suggesting
the existence of a partially unfolded conformation. The nMOMP first disrupts its tertiary
structure and then loses secondary structure under thermal stress. The disruption of tertiary
structure prior to secondary structure combined with aggregation is characteristic of the
appearance of molten globule states.29 Such intermediate states are not as commonly seen with
membrane compared to soluble proteins. Both light scattering and optical density
measurements were employed to assess the aggregation behavior of nMOMP. Both techniques
reveal that the protein has a greater tendency to form larger species at pH 3-5 while only slight
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traces of associated proteins are observed in the right-angle light scattering experiments which
are more sensitive than turbimetric measurements. All of the conformational events described
above are well summarized in the nMOMP EPD over the experimental pH and temperature
range examined.
Studies of the pH and thermal stability of native MOMP trimer performed by Sun et. al. have
shown the trimer to be stable in SDS between pH 5 and 8.11 At pH 4 and 9, however, the trimer
was partially dissociated and at pH 3 and 10 was completely dissociated11. In addition, the
trimer was found to be stable from 4-37 °C.11 At 45°C, the trimer started to dissociate into
monomers and completely dissociated following incubation at 65 °C.11 These results were
obtained, however, using of SDS-PAGE and analyzed by Western blotting.11 Our results using
different analytical techniques have found a similar thermal dependence of nMOMP. In
contrast, no apparent pH dependence was observed at low temperatures. In addition, the CD
and light scattering data in our studies show nMOMP to behave rather differently at pH 5
compared to pH 6-8 at high temperatures. We find that nMOMP is more stable in the pH range
of 6-8 at temperature below 50 °C.
In this study, we selected five molecules that were identified as having stabilization effects on
a native MOMP of a different serovar (data not shown). The choice of these particular
excipients covers a wide range of molecule types. All five selections are shown to inhibit the
aggregation of nMOMP by shifting the aggregation event to higher temperatures (~10 °C
difference). When incubated with nMOMP at 60 °C, these excipients are able to prevent the
aggregation of the protein for at least up to 2 h. Although long-term storage studies have not
been conducted, these excipients have the potential to further stabilize the protein at lower
temperatures. Intrinsic fluorescence and CD experiments were repeated for nMOMP in the
presence of these excipients. No significant stabilization was observed in either tertiary or
secondary structure. This suggests that the mechanism of stabilization is not by protecting the
native protein conformation from heat-induced structural change but rather by shielding the
surface of the protein and interfering with protein-protein interactions. The precise mechanism
by which the excipients inhibit the aggregation of proteins is in general not entirely clear.
Stabilization of proteins by sugars, polyols and amino acids has been extensively studied and
is thought in many cases to be due to non-specific effects such as preferential hydration.30-32
The presence of surfactants such as Brij35 has been shown to prevent or reduce unfolding of
proteins at liquid/air or liquid/solid interfaces.33 In this case, the excipients prevent the
aggregation but have no apparent effect on the structure or conformational stability of nMOMP,
the stabilization mechanism is probably due to direct binding of the excipients to the protein
surface. One of the greatest challenges to the development of stable solution formulation of
vaccines is to prevent aggregation over long periods under acceptable storage conditions (e.g.
2-8°C). The stabilizers analyzed in this study demonstrate a striking ability to inhibit
aggregation under thermal stress. These results thus provide a reasonable starting point for
further formulation development of human vaccines.
Screening of potential excipients for protein pharmaceuticals is often performed using
calorimetric techniques, such as differential scanning calorimetry (DSC). Upon identification
based on increase in Tm determined by this method, excipients are subjected to optimization
studies under normal storage conditions and in appropriate delivery devices. Although
providing direct evidence of stabilization, DSC usually requires higher protein concentrations.
Vaccines, however, are generally formulated at relatively low concentrations (e.g. 10-100 μg/
mL). The spectroscopic measurements employed in this study provide analytical tools that can
be used to assess excipient effects on protein samples at lower concentrations. Furthermore,
the collection of physical methods employed here targets different physical properties of a
protein, including secondary and tertiary structure changes as well as aggregation behavior.
This permits the effects of the excipients to be better understood. We also demonstrated that
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information obtained from EPD analysis (i.e. apparent phase boundary conditions) can be used
to develop robust assays to measure protein stabilization. Further evaluation of these excipients,
however, requires additional efforts including chemical degradation and immunogenicity
studies. Results obtained in this study concerning excipients can also be applied to the
investigation of recombinant forms of MOMP which are more desirable candidates for actual
vaccine production. The recombinant form of MOMP, like other membrane proteins, is
extremely difficult to refold in vitro due to the tendency of the oligomeric protein to form
insoluble aggregates and the presence of redox-sensitive cysteine residues. With the aid of
appropriate excipients, however, it should be possible to extend the solubility of the protein
and, subsequently, promote proper folding.
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Secondary structure of nMOMP. Far-UV CD spectra (200-250 nm) were obtained for nMOMP
at pH 3-8 (0.2 mg/mL). Scans at both the beginning (10 °C) and the end (87.5 °C) of the thermal
melt are shown. The error bars were determined from duplicate measurements.
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CD signal at 216 nm of nMOMP. The CD signal at 216 nm of nMOMP (0.2 mg/mL) is plotted
as a function of temperature as an indication of secondary structure stability under thermal
stress. Scans were obtained at 2.5 °C increments for duplicate samples (indicated by error bars).
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Intrinsic fluorescence of nMOMP. The intrinsic fluorescence peak position of nMOMP (0.1
mg/mL) is shown as temperature increases from 10 to 87.5 °C. All results were obtained from
duplicate experiments.
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Static light scattering of nMOMP. The static light scattering intensity at 295 nm was recorded
during the intrinsic fluorescence measurements of nMOMP (0.1 mg/mL). The intensity is
shown as a function of temperature. The error bars indicate standard errors from duplicate
measurements.
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Turbidity measurement of nMOMP. The OD350 was monitored for nMOMP at 0.05 mg/mL.
The increase in optical density is displayed as an indication of the formation of larger protein
species (i.e. aggregates) when temperature increases. Standard errors from duplicates are
presented in the form of error bars.
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Empirical phase diagram (EPD) of nMOMP. The EPD of nMOMP was generated using an
averaged CD signal at 216 nm, intrinsic fluorescence peak position, static light scattering
intensity and OD350 measurement. Data were normalized within each technique and the
presence of changes in the spectroscopic measurements is manifested by color change in the
EPD over the indicated pH (3-8) and temperature (10-87.5 °C) range. The coherent color
distribution usually indicates the continuity of a particular physical state of the protein while
conformational changes and associated/dissociation phenomena are seen as color changes.
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Effects of excipients on nMOMP stability. The nMOMP protein (0.05 mg/mL) at pH 5 was
incubated at elevated temperature (60 °C) with five different excipients for two hours and the
OD350 is shown in (A) from two independent experiments. The static light scattering results
of nMOMP (0.05 mg/mL) in the presence of five excipient molecules are plotted against
increasing temperature in (B).
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Table 1
Effects of selected compounds on the stability of nMOMP tertiary structure.
Excipient1 Transition midpoint (°C)2
None 42.4 ± 0.3
0.3 M Arginine 42.0 ± 0.2
0.1% Brij 35 42.1 ± 0.7
0.3 M Guanidine 41.0 ± 0.3
0.2 M Sodium Citrate 43.3 ± 0.2
20% Sucrose 41.9 ± 0.3
1
Excipients were added to 0.1 mg/mL nMOMP (pH 5) at indicated concentrations. Percentages are based on w/v ratio.
2
The intrinsic fluorescence was measured for nMOMP in the presence of excipients as a function of temperature from 10 to 87.5 °C. The midpoint of the
thermally-induced transition in fluorescence peak position was determined using the Sigmoidal fitting tool in Origin 7.0. Calculated results are presented
in the format of “average ± standard error”.
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